Non-invasive Diagnostics of Liver Fibrosis

Mihaylov, R.; Pencheva, Blagovesta; Stoeva, D.; Ruseva, A.

doi:10.1515/amb-2017-0009

Cited by 2 publications

(2 citation statements)

References 28 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrosis biomarkers can only be direct or indirect markers. Both types of markers can be individually used or in combination which is frequently happening to increase the diagnostic reliability [5,6]. There are multiple biological processes that the protein family of S100 has been reported to participate, such as cell motility, growth, transcription, signal transduction, apoptosis, and cell survival, which were correlated to tumorigenesis and normal development [7].…”

Section: Introductionmentioning

confidence: 99%

Detection of liver fibrosis stages in patients with hepatitis C virus infection by non-invasive tool

Serag

Eysa

2021

Egypt Liver Journal

View full text Add to dashboard Cite

Background S100A14 is a novel significant individual from S100 proteins family. Its significance is because of its part in tumorigenesis and metastasis process. Elevated level of S100A14 was associated with poor tumor differentiation. A relatively high dose of S100A14 was capable to induce cell injuries. It was discovered that S100A14 is seen at the extracellular medium. S100A14 induces the activation of apoptotic mediators and cell apoptosis. The aim of this study is to assess the clinical response of S100A14 in the detection the stages of liver fibrosis in patients of chronic HCV. ELISA was used to detect the levels of serum S100A14 in both different stages of fibrosis of the liver and control groups, and then, they were noticed together with the results of fibroscan. Other noninvasive markers of fibrosis were calculated such as APRI, AAR, and FIB-4 score. Results Protein expression level of S100A14 was positive correlated significantly with stages of fibrosis. Conclusion Measurement of serum level of S100A14 is a useful non-invasive marker for detection of the stages of liver fibrosis in patients of chronic HCV. Combinations of measuring S100A14 level to FIB-4 or S100A14 to APRI give a sensitive tool for diagnosing significant fibrosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Detection of liver fibrosis stages in patients with hepatitis C virus infection by non-invasive tool

Serag

Eysa

2021

Egypt Liver Journal

View full text Add to dashboard Cite

show abstract

“…Mihaylov et al [27] stated that HA could be used as in clinical practice to exclude advanced fibrosis because of its high negative predictive value (98-100%); thus it is the most accurate marker predicting advanced fibrosis in chronic hepatitis C and B, steatosis and alcoholic liver disease.…”

Section: Discussionmentioning

confidence: 99%

Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients

Rewisha

Salman

Alhaddad

et al. 2021

ceh

View full text Add to dashboard Cite

Introduction:Fibrosis is an inevitable complication of chronic hepatitis C virus (HCV) infection. Direct acting antivirals (DAAs) radically treated HCV and were suggested to ameliorate fibrosis. Silymarin (a natural herbal remedy) was proposed to further decrease hepatic inflammation and fibrosis. Consequently, serial monitoring of liver fibrosis status by different biomarkers is needed. Aim of the study: To assess hyaluronic acid (HA) as a potential marker of fibrosis regression after DAAs in chronic HCV patients; in addition, to evaluate silymarin as an agent that, beside DAAs, could further improve fibrosis. Material and methods: Two groups were included (150 patients each). Group 1 received DAAs only, while group 2 received DAAs followed by silymarin. Hyaluronic acid and FIB4 score were assessed at baseline before treatment and 1 year after inclusion in the study. Results: We found that DAA therapy alone or in combination with silymarin resulted in a significant reduction in serum HA level. However, the latter case showed a statistically significantly greater reduction (p = 0.034). Mean ±SD of serum HA level was 211.8 ±179.9 and 143.3 ±123.9 µg/l before and one year after inclusion respectively in group 1 (p = 0.001) and also, its level decreased significantly in group 2 from 188.3 ±211.8 µg/l before receiving DAAs to 126.4 ±136.9 µg/l at one year after inclusion (p = 0.001). There was no significant difference between the 2 studied groups as regards FIB-4 at 1 year after inclusion (p = 0.103). Conclusions: Hyaluronic acid might be a sensitive marker for monitoring fibrosis regression in treated chronic HCV patients. Adding silymarin to treatment protocols could ameliorate the fibrosis status.

show abstract

Non-invasive Diagnostics of Liver Fibrosis

Abstract: Abstract. Detecting new units of pathogenesis in the liver

Cited by 2 publications

References 28 publications

Detection of liver fibrosis stages in patients with hepatitis C virus infection by non-invasive tool

Detection of liver fibrosis stages in patients with hepatitis C virus infection by non-invasive tool

Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients

Contact Info

Product

Resources

About